BRCA2 and ovarian carcinoma: It has been found that inhibiting VEGFR3 and blocking the expression of VEGF-C in ovarian cancer can reduce BRCA1 and BRCA2, which is conducive to chemotherapy and the subsequent use of PARP inhibitors [78].